Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex Pharmaceuticals has a robust underlying business along with some exposure to ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

This run could be short-lived.

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to treat ...

BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.

We are in the golden age of science and technology, advancements in gene editing and ASO therapies are allowing doctors to deliver targeted, and in some cases one-time, interventions for conditions ...

For one, Cathie Wood can't get enough of CRSP stock, recently picking up another 438,000 shares across the ARK Innovation ETF ...

If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

This episode includes a 4D simulation, a new gene insertion technique, dementia blood biomarkers, and updates from uniQure and Moderna.

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.